Antiarrhythmic drug-induced internalization of the atrial-specific K+ channel Kv1.5

Circulation Research

Volumn 104, Issue 12, 2009, Pages 1390-1398

  Schumacher, Sarah M ^a   McEwen, Dyke P ^a   Zhang, Lian ^a   Arendt, Kristin L ^a   Van Genderen, Kristin M ^a   Martens, Jeffrey R ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Antiarrhythmic; Cardiac; Potassium channel; Trafficking

Indexed keywords

POTASSIUM CHANNEL BLOCKING AGENT; POTASSIUM CHANNEL KV1.5; QUINIDINE; ANTIARRHYTHMIC AGENT; KCNA5 PROTEIN, HUMAN; MUSCLE PROTEIN; POTASSIUM; PROTEIN SUBUNIT;

ANIMAL CELL; ANIMAL CELL CULTURE; ARTICLE; CELL ISOLATION; DOSE RESPONSE; DRUG BINDING; ELECTROPHYSIOLOGY; ELECTROPORATION; ENDOCYTOSIS; HEART ARRHYTHMIA; HEART ATRIUM; HEART ATRIUM FIBRILLATION; HEART MUSCLE CELL; IMMUNOCYTOCHEMISTRY; INTERNALIZATION; LONG TERM CARE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TEMPERATURE DEPENDENCE; ANIMAL; CELL LINE; DRUG EFFECT; GENETICS; HUMAN; ION TRANSPORT; METABOLISM; PROTEIN TRANSPORT;

ANIMALS; ANTI-ARRHYTHMIA AGENTS; ATRIAL FIBRILLATION; CELL LINE; HEART ATRIA; HUMANS; ION TRANSPORT; KV1.5 POTASSIUM CHANNEL; MICE; MUSCLE PROTEINS; MYOCYTES, CARDIAC; POTASSIUM; PROTEIN SUBUNITS; PROTEIN TRANSPORT; QUINIDINE;

EID: 67650215357     PISSN: 00097330     EISSN: 15244571     Source Type: Journal    
DOI: 10.1161/CIRCRESAHA.108.192773     Document Type: Article

References (35)

1. Lafuente-Lafuente C, Mouly S, Longas-Tejero MA, Bergmann JF. Antiarrhythmics for maintaining sinus rhythm after cardioversion of atrial fibrillation. Cochrane Database Syst Rev. 2007:CD005049.
2. Lafuente-Lafuente C, Mouly S, Longas-Tejero MA, Mahe I, Bergmann JF. Antiarrhythmic drugs for maintaining sinus rhythm after cardioversion of atrial fibrillation: a systematic review of randomized controlled trials. Arch Intern Med. 2006;166:719-728.
3. Nattel S, Carlsson L. Innovative approaches to anti-arrhythmic drug therapy. Nat Rev Drug Discov. 2006;5:1034-1049.
4. Waldo AL. A perspective on antiarrhythmic drug therapy to treat atrial fibrillation: there remains an unmet need. Am Heart J. 2006;151:771-778.
5. Feng J, Wible B, Li GR, Wang Z, Nattel S. Antisense oligodeoxynucle- otides directed against Kv1.5 mRNA specifically inhibit ultrarapid delayed rectifier K+ current in cultured adult human atrial myocytes. Circ Res. 1997;80:572-579.
6. Olson TM, Alekseev AE, Liu XK, Park S, Zingman LV, Bienengraeber M, Sattiraju S, Ballew JD, Jahangir A, Terzic A. Kv1.5 channelopathy due to KCNA5 loss-of-function mutation causes human atrial fibrillation. Hum Mol Genet. 2006;15:2185-2191.
7. van der Heyden MA, Smits ME, Vos MA. Drugs and trafficking of ion channels: a new pro-arrhythmic threat on the horizon? Br J Pharmacol. 2008;153:406-409.
8. Wible BA, Hawryluk P, Ficker E, Kuryshev YA, Kirsch G, Brown AM. HERG-Lite: a novel comprehensive high-throughput screen for drug-induced hERG risk. J Pharmacol Toxicol Methods. 2005;52:136-145.
9. Ficker E, Kuryshev YA, Dennis AT, Obejero-Paz C, Wang L, Hawryluk P, Wible BA, Brown AM. Mechanisms of arsenic-induced prolongation of cardiac repolarization. Mol Pharmacol. 2004;66:33-44.
10. Drolet B, Simard C, Roden DM. Unusual effects of a QT-prolonging drug, arsenic trioxide, on cardiac potassium currents. Circulation. 2004; 109:26-29.
11. McEwen DP, Schumacher SM, Li Q, Benson MD, Iniguez-Lluhi JA, Van Genderen KM, Martens JR. Rab-GTPase-dependent endocytic recycling of Kv1.5 in atrial myocytes. J Biol Chem. 2007;282:29612-29620.
12. Martens JR, Navarro-Polanco R, Coppock EA, Nishiyama A, Parshley L, Grobaski TD, Tamkun MM. Differential targeting of Shaker-like potassium channels to lipid rafts. J Biol Chem. 2000;275:7443-7446.
13. Zlochiver S, Munoz V, Vikstrom KL, Taffet SM, Berenfeld O, Jalife J. Electrotonic myofibroblast-to-myocyte coupling increases propensity to reentrant arrhythmias in two-dimensional cardiac monolayers. Biophys J. 2008;95:4469-4480.
14. Snyders J, Knoth KM, Roberds SL, Tamkun MM. Time-, voltage-, and state-dependent block by quinidine of a cloned human cardiac potassium channel. Mol Pharmacol. 1992;41:322-330.
15. Miesenbock G, De Angelis DA, Rothman JE. Visualizing secretion and synaptic transmission with pH-sensitive green fluorescent proteins. Nature. 1998;394:192-195.
16. Caballero R, Pourrier M, Schram G, Delpon E, Tamargo J, Nattel S. Effects of flecainide and quinidine on Kv4.2 currents: voltage dependence and role of S6 valines. Br J Pharmacol. 2003;138:1475-1484.
17. Yang T, Snyders DJ, Roden DM. Inhibition of cardiac potassium currents by the vesnarinone analog OPC-18790: comparison with quinidine and dofetilide. J Pharmacol Exp Ther. 1997;280:1170-1175.
18. Chen FS, Steele D, Fedida D. Allosteric effects of permeating cations on gating currents during K+ channel deactivation. J Gen Physiol. 1997; 110:87-100.
19. White NJ. Cardiotoxicity of antimalarial drugs. Lancet Infect Dis. 2007; 7:549-558.
20. Snyders DJ, Yeola SW. Determinants of antiarrhythmic drug action. Electrostatic and hydrophobic components of block of the human cardiac hKv15 channel. Circ Res. 1995;77:575-583.
21. Decher N, Kumar P, Gonzalez T, Pirard B, Sanguinetti MC. Binding site of a novel Kv1.5 blocker: a "foot in the door" against atrial fibrillation. Mol Pharmacol. 2006;70:1204-1211.
22. Decher N, Pirard B, Bundis F, Peukert S, Baringhaus KH, Busch AE, Steinmeyer K, Sanguinetti MC. Molecular basis for Kv1.5 channel block: conservation of drug binding sites among voltage-gated K+ channels. J Biol Chem. 2004;279:394-400.
23. Drolet B, Simard C, Mizoue L, Roden DM. Human cardiac potassium channel DNA polymorphism modulates access to drug-binding site and causes drug resistance. J Clin Invest. 2005;115:2209-2213.
24. MaciaE, EhrlichM, MassolR, BoucrotE, BrunnerC, Kirchhausen T. Dynasore, a cell-permeable inhibitor of dynamin. Dev Cell. 2006;10:839-850.
25. Kirchhausen T, Macia E, Pelish HE. Use of dynasore, the small molecule inhibitor of dynamin, in the regulation of endocytosis. Methods Enzymol. 2008;438:77-93.
26. Newton AJ, Kirchhausen T, Murthy VN. Inhibition of dynamin completely blocks compensatory synaptic vesicle endocytosis. Proc Natl Acad Sci USA. 2006;103:17955-17960.
27. Choi WS, Khurana A, Mathur R, Viswanathan V, Steele DF, Fedida D. Kv1.5 surface expression is modulated by retrograde trafficking of newly endocytosed channels by the dynein motor. Circ Res. 2005;97: 363-371.
28. Smillie KJ, Cousin MA. Dynamin I phosphorylation and the control of synaptic vesicle endocytosis. Biochem Soc Symp. 2005:87-97.
29. Steinbeck G, Remp T, Hoffmann E. Effects of Class I drugs on atrial fibrillation. J Cardiovasc Electrophysiol. 1998;9:S104-S108.
30. Colatsky TJ, Follmer CH, Starmer CF. Channel specificity in antiarrhythmic drug action. Mechanism of potassium channel block and its role in suppressing and aggravating cardiac arrhythmias. Circulation. 1990; 82:2235-2242.
31. Siddoway LA, Roden DM, Woosley RL. Clinical pharmacology of old and new antiarrhythmic drugs. Cardiovasc Clin. 1985;15:199-248.
32. Camm AJ. Safety considerations in the pharmacological management of atrial fibrillation. Int J Cardiol. 2008;127:299-306.
33. Colatsky TJ. Mechanisms of action of lidocaine and quinidine on action potential duration in rabbit cardiac Purkinje fibers. An effect on steady state sodium currents? Circ Res. 1982;50:17-27.
34. Slawsky MT, Castle NA. K+ channel blocking actions of flecainide compared with those of propafenone and quinidine in adult rat ventricular myocytes. J Pharmacol Exp Ther. 1994;269:66-74.
35. Zhang L, Foster K, Li Q, Martens JR. S-acylation regulates Kv1.5 channel surface expression. Am J Physiol Cell Physiol. 2007;293: C152-C161.